Michael Sapienza, Chief Executive Officer of the Colorectal Cancer Alliance, shared on LinkedIn:
“We have never had more promising tools to battle cancer. But we still have a fundamental problem: too many CRC patients are not getting the information, testing, and treatment options that could change their outcomes.
That disconnect is at the center of this The New York Times article by Gina Kolata, ‘New Cancer Drugs Are Revolutionary. Why Don’t More Patients Get Them?’ It spotlights the story of John Ebers, a CRC patient whose first doctor didn’t tell him about biomarker testing for targeted therapies, which could have provided an alternative to the toxic effects of chemotherapy.
Dr. Christopher Lieu, a scientific medical advisor to the Colorectal Cancer Alliance and scientific co – chair of Alliance’s Project Cure CRC initiative is quoted in the article about the importance of biomarker testing in finding better, potentially less toxic treatments, that could help prolong patients’ lives.
Thank you to the Times and Gina for bringing awareness to this important issue. It is one that the Alliance is working to solve through Project Cure CRC and KLEOS, the first ever adaptive clinical trial platform bringing better treatments to CRC patients faster.
Enough CRC. Let’s end this.
Read the full New York Times article here.
To learn more about KLEOS and partner with us to end this disease, visit.”
Other articles featuring Michael Sapienza on OncoDaily.